The Food and Drug Administration (FDA)Â has approved the first DNA test to help healthcare professionals gauge the progress of antiviral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.
The COBAS AmpliPrep/COBAS TaqMan CMV Test is a viral load test that can help determine the amount of CMV nucleic acid present in a sample of a patients blood plasma.
While a patient is undergoing anti-CMV therapy, a clinician can use the device to perform a series of tests to look for changes in a patients CMV viral load. A significant decrease in viral load from one test to the next may indicate that a particular therapy is effective, while an increase or no change may indicate the need for a different therapy. When used along with other clinical and laboratory data, this information can aid clinicians to manage and optimize patient care.
CMV is a common virus that can cause severe diseases such as pneumonia or colitis in people with weakened immune systems, including solid organ transplant patients. Solid organ transplants include heart, lung, pancreas, kidney, or small intestine transplants. Transplants of tissue or cells, such as bone marrow, skin, or muscle, are not included.
The U.S. Health Resources and Services Administrations Organ Procurement and Transplantation Network reports that there were 28,538 solid organ transplants in the United States in 2011.Â
Tests such as the COBAS AmpliPrep/COBAS TaqMan CMV Test can play an important role in helping healthcare professionals appropriately treat patients, says Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostic Device Evaluation and Safety in FDAs Center for Devices and Radiological Health.
The FDAs approval of the COBAS AmpliPrep/COBAS TaqMan CMV Test was based on information that included an assessment of the test's accuracy in measuring viral load and its ability to accurately measure variations in the amount of CMV virus.
The agency evaluated clinical data from a randomized, three-site study of frozen plasma samples from 211 kidney transplant patients with confirmed CMV diagnosis who underwent a seven-week course of anti-CMV therapy. Study results showed that a lower baseline viral load can predict a shorter time to resolution of CMV disease, and that significant declines in viral load are highly correlated to resolution of CMV disease.Â
The test is not approved for use as a screening test for the presence of CMV DNA in blood or blood products or as a diagnostic test to diagnose CMV infection. It has not been evaluated in newborns, pediatric patients, AIDS, or other immunocompromised patients. Before switching to the COBAS AmpliPrep/COBAS TaqMan CMV Test, clinicians should compare and understand how the test method and results may differ from test methods and results currently used in their practice.
The COBAS AmpliPrep/COBAS TaqMan CMV Test is manufactured by the Roche Molecular Systems in Somerville, N.J.
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.